ARTHUR-D.-LITTLE
10.3.2021 09:02:06 CET | Business Wire | Press release
Arthur D. Little (ADL) today announced the promotion of seven of its consultants to the rank of Partner, in recognition of the expertise and depth of experience that each one brings to the company. These appointments represent a major milestone for ADL, with the company now boasting over 100 Partners within its global team. Over the past five years, ADL has doubled in size by pursuing a dynamic growth path, and one of the key tenets of its ongoing success is the development and promotion of its internal talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005042/en/
The latest appointments to Partner are as follows:
- Matteo Ainardi, Partner, Automotive and Manufacturing (AMG) and Strategy & Organization (S&O) Practices. Matteo joined ADL in 2016 and currently leads the company’s global Aerospace & Defense Center of Competence. His main focus is on supporting clients in the A&D ecosystem, focusing on strategy definition, organizational redesign and innovation management.
- Lokesh Dadhich, Partner, Telecommunication, Information, Media & Electronics (TIME) and Operations Management (OM) Practices. Lokesh joined ADL in 2007 and is based out of the company’s Dubai office. His main areas of expertise are in Digital Strategy, Customer Experience, and Operations Excellence topics. He advises clients in the TIME industry and beyond on strategy, operations, and transformation challenges.
- Naoya Furuta, Partner, Operations Management (OM) Practice. Naoya joined ADL’s Tokyo office as a Manager in 2016, and has experience across multiple industries, with a particular focus on manufacturing and construction. His main areas of expertise include company-wide strategic planning, corporate management, corporate reform, M&A advisory and PMI.
- Trung Ghi, Partner, Energy & Utilities (ENUT) Practice. With more than 20 years of experience in the oil and gas industry, Trung currently leads ADL’s ENUT Practice in South-East Asia, and has been responsible for opening a number of key accounts. He has been a driving force in positioning ADL as a go-to management consulting firm within SEA’s energy sector.
- Max Scherr, Partner, Strategy & Organization (S&O) Practice. With over 20 years of experience in strategy consulting as a senior executive, Max joined ADL in 2018 and leads the company’s S&O Practice in its Vienna office. His specializations include Digital Transformation, Information Security, Growth and Corporate Strategy.
- Ben Thuriaux-Alemán, Partner, Energy & Utilities (ENUT) and Technology & Innovation Management (TIM) Practices. With over 20 years of consulting experience, Ben has played a major role in developing ADL’s TIM Practice, and currently runs the company’s Global Innovation Excellence Benchmarking diagnostic. His particular focus is on aligning innovation with corporate strategy, and working on national innovation initiatives.
- Marten Zieris, Partner, Strategy & Organization (S&O) Practice. Marten joined ADL in 2010 and is based out of its Frankfurt office. He is responsible for the company’s competence center “Organization & Transformation” in Central Europe and supports international clients in large-scale transformations end to end, “from concept development to implementation”. Marten also has a specialist focus on consumer products businesses.
Ignacio García Alves, Chairman and CEO of Arthur D. Little, comments: “I would like to congratulate these new Partners – and welcome them as the first members of ADL’s ‘Generation 100’! Each promotion is richly deserved and a recognition of the vital contribution that each Partner makes to our company. At ADL, we strive to employ and develop consultants who are both entrepreneurs and team players, and aspire to deliver consultancy at the highest level – as such, having over 100 Partners within ADL truly is a momentous achievement.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom